This phase II trial investigated the safety and efficacy of a combined-modality treatment with rituximab (Rituxan) and fludarabine (Fludara) in patients with fludarabine- and anthracycline-naive chronic lymphocytic lymphoma (CLL).
W. E. Aulitzky
Advertisement
Articles by W. E. Aulitzky
Advertisement
Latest Updated Articles
- Phase II Study of Rituximab in Combination With Fludarabine in Patients With Chronic Lymphocytic Leukemia
Published: March 1st 2002 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Adjuvant Cemiplimab in Cutaneous Squamous Cell Carcinoma
2
Cryoablation Regimen Receives FDA Marketing Authorization for Breast Cancer
3
Collaborating to Overcome Barriers to Novel Hematologic Cancer Therapies
4
Salvage Nodal Radiation Shows Tolerability, Low Toxicity in Prostate Cancer
5
